Table 3.
Percentage of patients receiving medications at screening and at the end of the study
| Patients receiving medications, n (%) | Usual care (N = 461) |
Intervention (N = 524) |
||||
|---|---|---|---|---|---|---|
| Screening | Final visit | % Change | Screening | Final visit | % Change | |
| Any cardiovascular medications | 82.4 | 93.3 | 13.2 | 81.5 | 89.1 | 9.4 |
| Any antihypertensive | 80.9 | 91.1 | 12.6 | 77.9 | 84.7 | 8.8 |
| ACE inhibitors | 29.3 | 33.0 | 12.6 | 22.0 | 27.3 | 24.3 |
| ACE inhibitor combinations | 5.0 | 6.5 | 30.4 | 4.8 | 5.9 | 24.0 |
| ARBs | 14.3 | 17.4 | 21.2 | 14.1 | 16.0 | 13.5 |
| ARB combinations | 8.5 | 10.6 | 25.6 | 10.9 | 13.4 | 22.8 |
| Beta-blocking agents | 37.1 | 41.2 | 11.1 | 29.4 | 31.3 | 6.5 |
| CCBs | 22.1 | 27.3 | 23.5 | 23.9 | 28.8 | 20.8 |
| Diuretics | 28.0 | 32.5 | 16.3 | 15.3 | 20.2 | 32.5 |
| Other antihypertensives | 6.5 | 6.7 | 3.3 | 5.0 | 6.7 | 34.6 |
| Serum lipid-reducing agents | 23.9 | 38.8 | 62.7 | 27.1 | 42.0 | 54.9 |
| Aspirin | 4.1 | 5.2 | 26.3 | 8.2 | 10.9 | 32.6 |
| Peripheral vasodilators | 3.0 | 3.5 | 14.3 | 1.5 | 1.5 | 0 |
| Anti-obesity medications | 0 | 0 | 0 | 0.4 | 0.4 | 0 |
| Others* | 2.4 | 4.1 | 72.7 | 2.7 | 4.0 | 50.0 |
*
Including antihaemorrhoidals for topical use, corticosteroids and flavonoids. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.